Navigation Links
The North American Thrombosis Forum (NATF)* Honors Hospitals that Excel in the Prevention of Deep Vein Thrombosis (DVT)

BOSTON, Jan. 19 /PRNewswire/ -- The North American Thrombosis Forum (NATF), in coordination with Eisai Inc., announced today that three hospitals have been selected as recipients of the 2009 DVTeamCare Hospital Award.  This new award was established by Eisai to recognize hospitals that have made a significant commitment to preventing deep vein thrombosis (DVT) and its potentially fatal complications, including pulmonary embolism (PE).  

Throughout the year, NATF and Eisai invited healthcare professionals from across the country to nominate their hospital for the first annual DVTeamCare Hospital Award and share their protocols and implementation strategies for preventing DVT.  The award is an extension of NATF's goal of enhancing thrombosis education, prevention, diagnosis, and treatment to improve patient outcomes and Eisai's human health care (hhc) mission, which is to give first thought to patients and their families, and to increasing the benefits that health care provides.

The Johns Hopkins Hospital (Maryland) and the University of California, San Diego Medical Center tied as award recipients among hospitals with more than 200 beds.  Washington DC Veterans Affairs Hospital is the award recipient among hospitals with less than 200 beds.

"We reviewed a series of submissions focused on VTE prevention," said John Fanikos, RPh, MBA, Treasurer of NATF and Assistant Director of Pharmacy at the Brigham and Women's Hospital.  "The successful common denominator was multiple disciplines within a hospital, rolling up their sleeves, working together, and either using the tools available, or improving those tools, or creating new ones to improve VTE prophylaxis. The initiatives, the innovation, and the efforts were impressive."

  • The Johns Hopkins Hospital developed a mandatory computer-based decision support system to facilitate specialty-specific risk factor assessment and the application of risk-appropriate Venous Thromboembolism (VTE) prophylaxis.
  • The University of California, San Diego Medical Center designed, piloted, and implemented a VTE prevention protocol across all medical and surgical services to achieve sustained high rates of VTE prophylaxis.  
  • The Washington DC Veterans Affairs Medical Center designed a 7-step process that walks providers through an evidence-based medicine risk factor assessment to determine appropriate thromboprophylactic therapy.

The award-winning protocols for Hospital DVT Prophylaxis Strategies will be presented at a NATF hosted program on the afternoon (12:00 PM  - 4:00 PM) of April 9, 2010 at The Joseph B. Martin Conference Center at Harvard Medical School (77 Avenue Louis Pasteur, Boston, MA).  More information about the program and attendee registration is available online at or through the NATF office at 617-525-8326.

In addition, awardees will also be recognized among their peers and presented with a commemorative plaque during the NATF Annual Thrombosis Prevention Forum in Boston, Massachusetts on April 10, 2010.  After this presentation, the winning protocols and implementation plans will be made available at to help other hospitals enhance their efforts to prevent DVT.

Twenty-two hospitals submitted nominations, which were evaluated by an independent panel of three judges selected by NATF.  All judges are nationally and internationally recognized in the areas of thrombosis, hemostasis, and venous thromboembolism (VTE).  The judges scored the submissions based on four criteria developed by NATF:  intelligence/design of the protocol; implementation; results; and clarity/preparation of the nomination.

About Eisai Inc.

Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales).  The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion.  Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.  Headquartered in Woodcliff Lake, New Jersey, the company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  

About the North American Thrombosis Forum

NATF is a nonprofit organization that focuses on unmet needs and issues related to thrombosis and cardiovascular diseases such as deep vein thrombosis, pulmonary embolism, myocardial infarction, peripheral arterial occlusive disease, and stroke.  The five areas of major focus are: 1) basic translational research, 2) clinical research, especially diagnosis and therapy, 3) prevention and education, 4) public policy, and 5) advocacy.  NATF's legacy will be to improve patient care, outcomes, and public health by supporting thrombosis-related programs, such as novel research projects, innovative educational programs, public policy initiatives, regulatory issues and advocacy, and to broaden training opportunities for physicians, scientists, and other health professionals.  For more information about NATF, please visit

*NATF has been engaged to independently develop the criteria for and judge the Award and does not endorse or promote any product or service offered by Eisai Inc. or any Award nominee or recipient.

SOURCE Eisai Inc.



SOURCE Eisai Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Appoints New Leader of North American Business
2. Health IT Event Draws Experts to the Pacific Northwest
3. Revolutionary HD Surgical Footage from North Shore-LIJ Surgeon to be Broadcast for the First Time on ABCs 20/20, National Geographic Channel
4. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
5. Evanston Northwestern Healthcare Wins Award For Patient Safety
6. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
7. Northstar Healthcare Announces Option to Purchase a 60% Interest in The Palladium for Surgery - Dallas
8. Dermatologists identify North Texas leishmaniasis outbreak
9. Radiation Therapy Services Acquires North Carolina Facility
10. Northern Michigan Regional Health System Named a Working Mother 100 Best Company - 2007 by Working Mother Magazine
11. NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from reveals that behind the tendency to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology: